Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 2
5(50.0%)
Phase 1
5(50.0%)
10Total
Phase 2(5)
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT07576010Phase 1Active Not Recruiting

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Role: lead

NCT07489534Phase 2Recruiting

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

Role: lead

NCT07489989Phase 2Recruiting

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Role: lead

NCT07450391Phase 1Recruiting

EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

Role: lead

NCT07438067Phase 1Recruiting

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Role: lead

NCT07368634Phase 1Recruiting

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT07340723Phase 2Recruiting

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Role: lead

NCT07321301Phase 2Recruiting

Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

Role: lead

NCT07094477Phase 2Active Not Recruiting

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Role: lead

NCT07094464Phase 1Active Not Recruiting

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Role: lead

All 10 trials loaded